Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by enterobacteriaceae species producing AmpC or Extended-Spectrum β-Lactamases

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6490-6495

  Levasseur, Premavathy ^a,b   Girard, Anne Marie ^a,c   Lavallade, Ludovic ^a,d   Miossec, Christine ^a,e   Pace, John ^a,f   Coleman, Kenneth ^a,g  

^a Novexel SA   (France)

^b Enghien les Bains ^*  (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d Clinical Research   (Canada)

^e Vetoquinol France   (France)

^f Stiefel Laboratories Inc   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AVIBACTAM; BETA LACTAMASE AMPC; CEFOTAXIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CITROBACTER FREUNDII; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG EFFICACY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; SEPSIS;

EID: 84908638638     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03579-14     Document Type: Article

References (42)

1. Livermore D. 1996. Are all -lactams created equal? Scand. J. Infect. Dis. 101(Suppl):33-43.
2. Livermore DM, Woodford N. 2006. The -lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413-420. http://dx.doi.org/10.1016/j.tim.2006.07.008.
3. Bush K. 2010. Alarming -lactamase-mediated resistance in multidrugresistant Enterobacteriaceae. Curr. Opin. Microbiol. 13:558-564. http://dx.doi.org/10.1016/j.mib.2010.09.006.
4. Bradford PA. 2001. Extended-spectrum -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. http://dx.doi.org/10.1128/CMR .14.4.933-951.2001.
5. Coleman K. 2011. Diazabicyclooctans (DBOs): a potent new class of non -lactam -lactamase inhibitors. Curr. Opin. Microbiol. 14:550-555. http://dx.doi.org/10.1016/j.mib.2011.07.026.
6. Stachyra T, Péchereau MC, Bruneau JM, Claudon M, Frère JM, Miossec C, Coleman K, Black MT. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-lactam -lactamase inhibitor. Antimicrob. Agents Chemother. 54:5132-5138. http://dx.doi.org/10.1128/AAC.00568-10.
7. Ehmann DE, Jahić H, Ross PL, Gu R-F, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-lactam -lactamase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
8. Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaume C, Seys C, Stachyra T, Fairley M, Guitton M, Lampilas M. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-lactam -lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417. http://dx.doi.org/10.1093/jac/dkh358.
9. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extendedspectrum -lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056. http://dx.doi.org/10.1093/jac/dkn320.
10. Levasseur P, Girard AM, Delachaume C, Miossec C, Claudon M, Lowther J, Hodgson J. 2006. NXL104. A novel -lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae, abstr F-127. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
11. Levasseur P, Girard AM, Lavallade L, Miossec C, Shlaes D, Black MT, Pace J, Coleman K. 2009. In vitro antibacterial activity of ceftazidime (CAZ) in combination with the -lactamase inhibitor NXL104, abstr E-186. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
12. Citron DM, Tyrell KL, Merriam V, Goldstein EJ. 2011. In vitro activity of ceftazidime-NXL104 against 396 strains of -lactamase-producing anaerobes. Antimicrob. Agents Chemother. 55:3616-3620. http://dx.doi.org/10.1128/AAC.01682-10.
13. Dubreuil LJ, Mahieux S, Neut C, Miossec C, Pace J. 2012. Antianaerobic activity of a new -lactamase inhibitor NXL104 in combination with -lactams and metronidazole. Int. J. Antimicrob. Agents 39:500-504. http://dx.doi.org/10.1016/j.ijantimicag.2012.02.013.
14. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with -lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum -lactamases and class C -lactamases. Antimicrob. Agents Chemother. 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
15. Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329. http://dx.doi.org/10.1093/jac/dkp197.
16. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with -lactams against Klebsiella pneumoniae isolates producingKPCcarbapenemases. Antimicrob. Agents Chemother. 53:3599-3601. http://dx.doi.org/10.1128/AAC.00641-09.
17. Aktaş Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with -lactams against Gram-negative bacteria, including OXA-48 -lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39:86-89. http://dx.doi.org/10.1016/j.ijantimicag .2011.09.012.
18. Nordman P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
19. Bush K, Fisher JF. 2011. Epidemiological expansion, structural studies, and clinical challenges of new -lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 65:455-478. http://dx.doi.org/10.1146/annurev-micro-090110-102911.
20. Levasseur P, Girard AM, Miossec C, Lowther J, Rangaraju M, Hodgson J. 2005. Efficacy of NXL104, a novel -lactamase inhibitor, in combination with ceftazidime in murine septicemia and pneumonia, abstr F-1164. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC.
21. Levasseur P, Girard AM, Lavallade L, Miossec C, Shlaes D, Black MT, Pace J, Coleman K. 2009. Efficacy of ceftazidime (CAZ)/NXL104 combination in murine septicemia caused by CTX-M producing Enterobacteriaceae species, abstr A1-005. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
22. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. 2011. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55:82-85. http://dx.doi.org/10.1128/AAC.01198-10.
23. Merdjan H, Girard AM, Miossec C, Robertson M, Levasseur P. 2009. Pharmacokinetics (PK) and efficacy of ceftazidime (CAZ)/NXL104 combination in a murine pneumonia model caused by an AmpC-producing Klebsiella pneumoniae, abstr A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
24. Levasseur P, Girard AM, Lavallade L, Miossec C, Shlaes D, Black MT, Pace J, Coleman K. 2010. Efficacy of ceftazidime (CAZ)/NXL104 combination in murine septicemia caused by extended spectrum -lactamases and AmpC producing Enterobacteriaceae species, abstr P-1564. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis. Meet., Vienna, Austria.
25. Cottagnoud P, Merdjan H, Acosta F, Levasseur P, Cottagnoud M, Lowther J, Stucki A, Rangaraju M, Miossec C. 2007. Pharmacokinetics of the new -lactamase inhibitor NXL104 in an experimental rabbit meningitis model; restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K. pneumoniae, abstr F-321. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
26. Borgonovi M, Miossec C, Lowther J. 2007. The efficacy of ceftazidime combined with NXL104, a novel -lactamase inhibitor, in a mouse model of kidney infections induced by -lactamase producing Enterobacteriaceae, abstr P-794. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis., Munich, Germany.
27. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin M-E, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56: 6137-6146. http://dx.doi.org/10.1128/AAC.00851-12.
28. Mendes RE, Kiyota KA, Monteiro J, Castenheira M, Andrade SS, Gales AC, Pignatari AC, Jukit S. 2007. Rapid detection and identification of metallo-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J. Clin. Microbiol. 45:544-547. http://dx.doi.org/10.1128/JCM.01728-06.
29. Pérez-Pérez FJ, Hanson D. 2002. Detection of plasmid-mediated AmpC -lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162. http://dx.doi.org/10.1128/JCM.40.6.2153-2162 .2002.
30. Walther-Rasmussen J, Hoiby N. 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57:373-383. http://dx.doi.org/10.1093/jac/dki482.
31. Clinical and Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
32. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st international supplement, M100-S21, vol 31, no 1. Clinical and Laboratory Standards Institute, Wayne, PA.
33. Finney DJ. 1971. Probit analysis. Cambridge University Press, Cambridge, United Kingdom.
34. Coleman K, Levasseur P, Girard AM Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against -lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob. Agents Chemother. 58:3366-3372. http://dx.doi.org/10.1128/AAC.00080-14.
35. Akova M, Yang Y, Livermore D. 1990. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed class 1-lactamases. J. Antimicrob. Chemother. 25:199-208. http://dx.doi.org/10.1093/jac/25.2.199.
36. Bonnet R. 2004. A growing group of extended-spectrum -lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14. http://dx.doi.org/10.1128/AAC.48.1.1-14.2004.
37. Tzouvelekis L, Tzelepi E, Tassios P, Legakis N. 2000. CTX-M 2000 -lactamases: an emerging group of extended-spectrum enzymes. Int. J. Antimicrob. Agents. 14:137-142. http://dx.doi.org/10.1016/S0924-8579(99)00165-X.
38. Miossec C, Claudon M, Levasseur P, Black MT. 2013. The -lactamase inhibitor avibactam (NXL104) does not induce ampC -lactamase in Enterobacter cloacae. Infect. Drug Resist. 6:235-240. http://dx.doi.org/10.2147/IDR.S53874.
39. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J. Antimicrob. Chemother. 68:1183-1192. http://dx.doi.org/10.1093/jac/dks523.
40. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. 2012. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28:1921-1931. http://dx.doi.org/10.1185/03007995.2012.748653.
41. Bush K. 2012. Improving known classes of antibiotics: an optimistic approach for the future. Curr. Opin. Pharmacol. 12:527-534. http://dx.doi.org/10.1016/j.coph.2012.06.003.
42. Lagacé-Wiens P, Walkty A, Karlowsky JA. 2014. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 9:13-25. http://dx.doi.org/10.2147/CE.S40698.